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Antipsychotic Drugs (APDs) are being widely prescribed to treat various disorders, including 
schizophrenia and bipolar disorder; however, abnormal glucose metabolism and weight gain have been 
reported with Atypical Anti-Psychotic drugs (AAPDs) that can lead to insulin-resistance and type 2 
diabetes mellitus. The study was designed to assess various biochemical parameters including insulin 
and blood sugar before and after exposure to APDs in order to exclude the involvement of psychiatric 
disorders and certain other factors in metabolic dysregulations. Fifty seven APDs-naïve patients with 
first episode psychosis were divided into six groups who received olanzapine, quetiapine, risperidone, 
aripiprazole, haloperidol or combination of olanzapine with escitalopram and haloperidol. The serum 
samples were taken before the intake of the first dose and then on follow-up. Decrease in the level of 
elevated insulin and glucose was observed post-treatment in some patients, while others were observed 
whose insulin and glucose levels increased post-treatment, yet some patients did not show any disturbance 
in the insulin and glucose levels. It is concluded that psychiatric disorders by itself, narcotics, cigarette 
smoking and use of oral snuff may be also be implicated in metabolic dysregulations. The effects of APDs 
on insulin and glucose in healthy volunteers might be different than in patients with psychiatric disorders.
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INTRODUCTION
Psychosis is a broad term that relates to a person not 
in touch with reality. as patient cannot distinguish between 
factual and fictional. Psychotic disorders involve striking 
disturbances of thought, perception, affect, and behavior 
(Pantelis et al., 2003). The mortality rate is two or three 
times more in psychotic patients especially schizophrenics 
than in general population. The antipsychotic drugs 
have been documented as a considerable cause of excess 
mortality rate in psychotic patients (Mitchell, Lord, 2010; 
Vancampfort et al., 2013). Atypical Antipsychotic Drugs 
(AAPDs) have been widely prescribed to treat psychosis 
and various other disorders, including schizophrenia and 
bipolar disorders. However, hyperglycemia and weight 
gain are reported with AAPDs (clozapine, olanzapine, 
quetiapine, risperidone and aripiprazole) that can lead to 
insulin-resistance and type 2 diabetes mellitus (Baptista, 
Parada, Hernandez, 1987). It is still controversial whether 
the metabolic abnormalities are associated with the 
psychiatric disorder(s) or the antipsychotic drugs (AAPDs) 
(Ballon et al., 2014; Baptista, Parada, Hernandez, 1987; 
Cope et al., 2005; Goldstein, 1999). Several studies 
have correlated weight gain with AAPDs by different 
mechanisms including orexigenic effect (hence larger food 
intake) and histamine H1 receptors antagonism (Ballon 
et al., 2014). AAPDs have been frequently reported to 
cause hyperglycemia, both in animals (Baptista, Parada, 
Hernadez, 1987) and humans (Bergman, Ader, 2005).
Several mechanisms of AAPDs to disturb glucose 
homeostasis have been hypothesized including blockade of iD
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M3 receptors on beta cells of the pancreas (Weston-Green, 
Huang, Deng, 2011), weight gain and adiposity (Gohlke et 
al., 2012), damage of beta cells (Chiu et al., 2006; Shah et 
al., 2015) and tissue resistance to insulin (Ebenbichler et al., 
2003). We have previously reported damage of pancreatic 
beta cells and rise in blood sugar with chronic olanzapine 
treatment, the later was observed in 8th week of a 14 weeks 
once daily dosing in male rats, but weight loss instead of 
gain was observed, perhaps due to use of male gender and 
restricted access to food (Shah et al., 2015). There are 
studies which have reported hyperinsulinemia in medicated 
schizophrenics (Weston-Green, Huang, Deng, 2013). Chiu 
and his colleagues have reported no change in the levels of 
fasting glucose and glucose stimulated fasting insulin in 
patients treated with olanzapine and risperidone for two 
weeks, however, insulin level was decreased in olanzapine 
group after two weeks (Chiu et al., 2006), which has been 
hypothesized to be due to impairment of pancreatic beta 
cell function. They have also reported hypoinsulinemia 
in a cohort of Taiwanese schizophrenics following first 2 
weeks treatment with olanzapine which returned to baseline 
by 4 weeks and hyperinsulinemia by 8 weeks (Chiu et al., 
2010). There are apparent contrasts in reports about effects 
of AAPDs on insulin release (Weston-Green, Huang, Deng, 
2013), perhaps due to difference in settings of the study, 
models being used and drug selected. Genetic variation 
and predisposing risks for diabetes are also important to be 
considered rather antipsychotic drugs only. 
Different techniques have been used to assess 
the concentration of insulin and/or c-peptide including 
hyperglycemic clamp and oral glucose tolerance tests 
(Manu et al., 2013; Meier et al., 2001; Newcomer et al., 
2002). The results are contrary whether AAPDs cause 
damage to beta cells (Newcomer et al., 2002; Shah et 
al., 2015), hyperinsulinemia (Manu et al., 2013; Weston-
Green, Huang, Deng, 2013) or the hypothesis that AAPDs 
particularly olanzapine and risperidone directly impair 
pancreatic cell function is incorrect (Sowell et al., 2002). 
We have already hypothesized in our previous study and 
there are reports that these metabolic abnormalities might 
be due to schizophrenia itself and other risk factors rather 
the AAPDs since schizophrenics are usually underweight 
with poor pulse control, low blood pressure, tachycardia 
and deranged lipid profile (Shah et al., 2015).
AAPDs might cause abnormalities in lipid 
metabolism via both obesity-related and obesity-urelated 
molecular pathways, but no attention has been paid to the 
assessment of even most easily measurable metabolic 
parameters (De Hert et al., 2012). These metabolic 
abnormalities including cardiovascular events have been 
correlated with weight gain induced by AAPDs, with the 
reports that clozapine and olanzapine have the greatest risk, 
risperidone and quetiapine with low to moderate risk while 
aripiprazole has the minimal potential risk of clinically 
significant weight gain. Asymptomatic elevation in liver 
enzymes have been reported with olanzapine, quetiapine, 
risperidone and certain other commonly used typical and 
atypical antipsychotic drugs (Garcia‐Unzueta et al., 2003; 
McManus, 1999). Elevated cholesterol and triglycerides 
levels have been reported with antipsychotic drugs (APDs) 
(Lindenmayer et al., 2003; McIntyre, McCann, Kennedy, 
2001) that could predispose patients to cardiovascular 
accidents. Neuroleptic Malignant Syndrome (NMS) has 
also been reported with AAPDs that is characterized 
by severe muscle rigidity, fever and elevation of CPK 
(Strawn et al., 2007). There are no reports on the effect of 
antipsychotic drugs on renal function in human.
The studies conducted so far in this context, report 
the effects of these drugs on some parameters while 
ignore the others. Results have been presented in parts 
which do not give proper picture of the mechanisms of 
APDs-induced toxicities. We therefore designed this 
study involving drug naïve schizophrenics/first episode 
psychotics to unveil the fact whether APDs are really 
responsible to cause metabolic abnormalities while 
assessing all of the related parameters 
METHODS AND MATERIAL 
Subjects and procedures
Antipsychotic drugs-naïve non-diabetic patients 
(n=57) with first episode psychosis admitted to psychiatry 
unit or who visited OPD, Medical Teaching Institution, 
Khyber Teaching Hospital, Peshawar, K.P, Pakistan or 
Sayed Psychiatry Clinic, Peshawar, were included in 
this study. Patients of either gender with no history of 
antipsychotics aging not less than 18 years were part of the 
study. The patients on olanzapine, quetiapine, risperidone, 
aripiprazole and haloperidol monotherapies were grouped 
as OLAN (n=8), QUET (n=8), RISP (n=8), ARIP (n=8) 
and HAL (n=8) respectively while patients receiving 
combination of olanzapine with escitalopram, diazepam 
(STAT, I.V), and haloperidol (STAT, I.M) were grouped as 
OLEDH (n=8). Six patients failed to report for follow-up 
and three were dropped due to non-compliance. The patients 
were followed for an average time period of 39 days for 
OLEDH, 40 days for QUET, 45 days for OLAN, 38 days 
for RISP, 30 days for ARIP and 33 days for haloperidol. 
All subjects gave written informed consent otherwise 
excluded from the study. Pregnant females, obese and 
those with complicating pathologies including diabetes, 
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and those with hepatic and renal impairment were not 
included in the study.
The patients were interviewed by consultants or 
medical officers to assess their mental state for differential 
diagnosis. Positive and negative syndrome scale (PANSS) 
and ICD-10 criteria were applied for proper diagnosis 
before the commencement of treatment. Drugs were 
chosen on the basis of patient condition, severity of the 
disease and age.
All procedures were approved by the Ethical 
Committee of the Department of Pharmacy, University of 
Peshawar (Reference number, 02/EC-14/Pharm)) and that 
of the Khyber Medical College/Khyber Teaching Hospital/
Khyber College of Dentistry, Peshawar (No-49/MBW/
KTH, dt. 30/10/2013).
Laboratory and clinical measurements
Body weight and random blood glucose
Random blood glucose (RBG) and body weight 
were assessed at the time of the first recruitment to study 
and then on follow-up visit. Abbott glucometer was used 
for blood glucose measurements before and after the 
treatment. The random glucose level more than 140 mg/
dl was considered disturbed glucose level. 
Insulin and c-Peptide
Blood samples were taken before the administration 
of the first dose of the selected drug and then on follow-up. 
The blood samples were centrifuged and the isolated serum 
samples were stored at -20 0C till analyzed for insulin 
and c-Peptide, at the Radioimmunoassay Laboratory 
(RIA), Institute of Radiotherapy and Nuclear Medicine 
(IRNUM), Peshawar. Insulin and c-Peptide IRMA Kits 
(Lot #. 150525-C) were purchased from Beckman Coulter, 
Czech Republic. The level greater than 26.5 µIU/mL was 
considered abnormal.
Procedure for assessment of insulin and c-peptide 
levels
All the reagents were allowed to stay at room 
temperature. The content of the vial (control) was 
reconstituted with distilled water, after 10 minutes gentle 
mixing was performed to avoid foaming. Wash solution 
was prepared by pouring the content of the vial into 
950 ml of distilled water followed by homogenization. 
Precipitation reagent was taken in a volume of 400 µL and 
added to 400 µL of control as well as unknown sample in 
a glass tube. The contents were shaken using vortex mixer 
followed by centrifugation for 15 minutes at 3000 g and 
4 °C.
Results were obtained by planting the tubes 
containing prepared solution in specialized sample 
cuvettes of the IRMA analyzer.
Assessment of% beta cells function (Matthews et al., 
1985)
The function of the pancreatic beta cells was 
assessed using the following formula.
Beta cell function (%) = 20 x insulin/glucose – 3.5
Assessment of insulin resistance (IR) (Matthews et al., 
1985)
Insulin resistance (near approximation) was 
measured by using the following formula.
Insulin resistance (IR) = insulin x glucose/22.5
Other biochemistry
Serum ALT, AST, amylase, lipase, cholesterol, 
triglycerides, blood urea, serum creatinine and CPK were 
assessed at Pakistan Health Research Council (PHRC), 
Khyber Medical College (KMC), Peshawar, using 
Microlab 300 (Merck, Germany).
STATISTICAL ANALYSIS 
Analysis of Variance (ANOVA), Bonferroni’s 
multiple comparison test was used to determine differences 
among groups (Level of significance, P≤0.05). Data were 
expressed as mean ± standard error of mean (SEM). Graph 
Pad Prism 5 (Graph Pad Software Inc. San Diego CA, 
USA) was used as a statistical tool of analysis.
RESULTS
Body weight and random blood glucose (RBG)
No significant gain in random blood glucose 
(Figure 1) and body weight (Figure 2) (P>0.05) was 
noticed in all patients during their treatment tenure. 
However, 14.03% of the total population showed 
elevated random blood glucose (RBG) before antipsychotics 
exposure. Among the addicted population, 38.46% (5/13 
patients) with addiction of cannabis/charas, 40% (2/5 
patients) with habit of smoking tobacco and 41.67% 
(5/12 patients) with the habit of using oral snuff (Naswar) 
were presented with abnormally elevated RBG levels 
before exposure to APD(s). Interestingly, the level of RBS 
decreased from abnormal to normal in 10.53% of the total 
population, but elevated from normal to abnormal in 8.77% 
of the total population. Out of the non-addicted population 
R. Shah, F. Subhan, S. M. Sultan, M. Haq, H. Ahmad, Q. R. Khan , G. Ali, Samiullah, Ihsanullah
Braz. J. Pharm. Sci. 2019;55:e17825Page 4 / 12
(27/57), 22.22% (6/27 patients) were found with elevated 
blood sugar. Only, 12.5% (1/8 patients) of the combination, 
QUET and RISP groups, 25% (2/8 patients) of the OLAN 
and ARIP groups and 0% (0/8 patients) of the HAL group 
were shown with elevated RBS levels (Table I).
Effect on the level of Insulin and c-peptide 
No statistically significant difference were observed 
in the level of insulin (Figure 3) and c-peptide (Figure 4) 
in drug treated groups compared to drug naïve patients 
FIGURE 1 - Effect of selected antipsychotics on random blood 
glucose: Antipsychotic-naïve patients were put on olanzapine 
in combination with escitalopram, diazepam (STAT, I.V) and 
haloperidol (STAT, I.M) (OLEDH, n=8), quetiapine (QUET, n=8), 
olanzapine (OLAN, n=8), risperidone (RISP, n=8), aripiprazole 
(n=8) or haloperidol (n=8) in therapeutic doses for an average 
time period of 39, 40, 45, 38, 30 and 33 days respectively showing 
no significant change in random blood glucose as compared 
to antipsychotics-naïve patients (n=8) (ANOVA followed by 
Bonferroni’s Multiple Comparison Test) (P > 0.05).
FIGURE 2 - Effect of selected antipsychotics on body weight: 
Antipsychotic-naïve patients were put on olanzapine in 
combination with escitalopram, diazepam (STAT, I.V) and 
haloperidol (STAT, I.M) (OLEDH, n=8), quetiapine (QUET, 
n=8), olanzapine (OLAN, n=8), risperidone (RISP, n=8), 
aripiprazole (n=8) or haloperidol (n=8) in therapeutic doses 
for an average time period of 39, 40, 45, 38, 30 and 33 days 
respectively showing no significant change in body weight 
as compared to antipsychotics-naïve patients (n=8) (ANOVA 
followed by Bonferroni’s Multiple Comparison Test) (P > 0.05).
TABLE I - Per cent wise distribution of patients with disturbed ( ≥ 140 mg/dl) glucose before and after exposure to antipsychotic 
treatment
DGBT 
(Drug naïve 
patients)
DGAT 
(OLEDH)
DGAT 
(QUET)
DGAT  
(OLAN)
DGAT  
(RISP)
DGAT  
(ARIP)
DGAT  
(HAL)
DGAT  
(All groups)
14.03 
(n=57)
12.5% 
(n=8)
12.5%
(n=8)
12.5% 
(n=8)
12.5% 
(n=8)
25% 
(n=8)
0% 
(n=8)
14.58% 
(n=48)
Level of RBG reduced with treatment (from abnormal to normal) 5/48 10.42%
Level of RBG elevated with treatment (from normal to abnormal) 6/48 12.5%
Patients abusing charas and cannabis presented with abnormal RBG levels (APDs-naive) 5/57 8.77%
Patients smoking tobacco presented with abnormal RBG levels (APDs-naive) 2/57 3.51%
Patients abusing oral snuff/naswar presented with abnormal RBG levels (APDs-naive) 5/57 8.77%
Total patients with any kind of drug dependence presented with elevated RBG (APDs-naive) 12/57 40%
DGBT=Deranged Glucose Before Treatment, DGAT= Deranged Glucose After Treatment, OLEDH= Group of patients who 
received olanzapine + Escitalopram i.v STAT + Diazepam i.v STAT + Haloperidol i.v STAT, QUET= Group of patients who 
received quetiapine, OLAN = Group of patients who received olanzapine, RISP= Group of Patients who received risperidone, 
HAL = Group of patients who received haloperidol, ARIP = Group of patients who received aripiprazole.
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(ANOVA, P>0.05).
However, it was observed that 21.05% of the total 
population presented abnormally elevated insulin levels 
when compared with reference. Similarly, 22.81% (13/57 
patients), 8.77% (5/57 patients), 21.05% (12/57) of the 
total population were found addicts of cannabis/charas, 
tobacco and oral snuff (Naswar) respectively. Thus 38.46% 
(5/13 patients) with addiction of cannabis/charas, 40% (2/5 
patients) with habit of smoking tobacco and 33.33% (4/12 
patients) with the habit of using oral snuff (Naswar) were 
presented with abnormally elevated insulin levels. Ten 
patients were found whose level decreased from abnormal 
to normal after the commencement of APD treatment, but 
the same number of patients were found whose insulin level 
elevated from normal to abnormal with the APD treatment. 
On the other hand, 40.74% (11/27 patients) of the 
non-addicts were shown with elevated insulin levels. 
Only 3.51% (2/8 patients), 7.02% (4/8 patients), 3.51% (2 
patients), 0% (0/8 patients), 7.02% (4/8 patients) and 0% 
(0/8 patients) of the combination (OLEDH), quetiapine 
(QUET), olanzapine (OLAN), risperidone (RISP), 
aripiprazole (ARIP) and haloperidol (HAL) groups 
respectively showed elevated insulin levels before the 
commencement of respective treatment (Table II).
DIBT=Deranged Insulin Before Treatment, DIAT= 
Deranged Insulin After Treatment, OLEDH= Group of 
patients who received olanzapine + Escitalopram i.v STAT 
+ Diazepam i.v STAT + Haloperidol i.v STAT, QUET= 
Group of patients who received quetiapine, OLAN = 
Group of patients who received olanzapine, RISP= Group 
of Patients who received risperidone, HAL = Group of 
patients who received haloperidol, ARIP = Group of 
patients who received aripiprazole.
Effect on beta cells function (%β) and insulin 
resistance (IR)
beta cells function (%β) (Figure 5) and insulin 
resistance (IR) (Figure 6) of drug naïve patients was 
compared with that of olanzapine (OLAN, n=8), 
quetiapine (QUET, n=8), risperidone (RISP, n=8), 
aripiprazole (ARIP, n=8), haloperidol (HAL, n=8) and 
combination of olanzapine with escitalopram, diazepam 
(STAT, I.V) and haloperidol (STAT, I.M) (OLEDH, n=8) 
which showed no significant change in the level of %β 
cell function and Insulin resistance (ANOVA followed by 
Bonferroni’s Multiple Comparison Test) (P >0.05). 
FIGURE 3 - Effect of selected antipsychotics on insulin: 
Antipsychotic-naïve patients were put on olanzapine in 
combination with esitalopram, diazepam (STAT, I.V) and 
haloperidol (STAT, I.M) (OLEDH, n=8), quetiapine (QUET, 
n=8), olanzapine (OLAN, n=8), risperidone (RISP, n=8), 
aripiprazole (n=8) or haloperidol (n=8) in therapeutic doses 
for an average time period of 39, 40, 45, 38, 30 and 33 days 
respectively showing no significant change in insulin as 
compared to antipsychotics-naïve patients (ANOVA followed 
by Bonferroni’s Multiple Comparison Test) (P > 0.05).
FIGURE 4 - Effect of selected antipsychotics on c-peptide: 
Antipsychotic-naïve patients were put on olanzapine in 
combination with esitalopram, diazepam (STAT, I.V) and 
haloperidol (STAT, I.M) (OLEDH, n=8), quetiapine (QUET, 
n=8), olanzapine (OLAN, n=8), risperidone (RISP, n=8), 
aripiprazole (n=8) or haloperidol (n=8) in therapeutic doses 
for an average time period of 39, 40, 45, 38, 30 and 33 days 
respectively showing no significant change in c-peptide as 
compared to antipsychotics-naïve patients (ANOVA followed 
by Bonferroni’s Multiple Comparison Test) (P > 0.05).
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TABLE II - Per cent wise distribution of patients with disturbed ( > 26.5 µIU/mL) insulin levels before and after exposure to 
antipsychotic treatment
DIBT 
(APDs native 
patients
DIAT 
(OLEDH)
DIAT 
(QUET)
DIAT 
(OLAN)
DIAT 
(RISP)
DIAT 
(ARIP)
DIAT 
(HAL)
DIAT 
(All drugs)
21.05% 
(n-57)
3.51% 
(n=8)
7.02% 
(n=8)
3.51% 
(n=8)
0% 
(n=8)
7.02% 
(n=8)
0% 
(n=8)
21.05% 
(n=48)
Insulin level reduced with treatment (From abnormal to normal) 10/48 17.54%
Insulin level increased with treatment (From normal to abnormal) 10/48 17.54%
Patients using cannabis and charas presented with DIBT 13/57 22.81%
Patients with smoking habits (tobacco) presented with DIBT 5/57 8.77%
Patients with addiction of Naswar/oral snuff presented with DIBT 12/57 21.05%
Total patients with any kind of addiction (Charas, smoking, naswar, cannabis) 30/57 52.63%
Patients without any addiction presented with DIBT 27/57 47.37%
DIBT=Deranged Insulin Before Treatment, DIAT= Deranged Insulin After Treatment, OLEDH= Group of patients who received 
olanzapine + Escitalopram i.v STAT + Diazepam i.v STAT + Haloperidol i.v STAT, QUET= Group of patients who received 
quetiapine, OLAN = Group of patients who received olanzapine, RISP= Group of Patients who received risperidone, HAL = Group 
of patients who received haloperidol, ARIP = Group of patients who received aripiprazole.
FIGURE 5 - Assessment of beta cells function (%β): 
Antipsychotic-naïve patients were treated with olanzapine in 
combination with escitalopram, diazepam (STAT, I.V) and 
haloperidol (STAT, I.M) (OLEDH, n=8), quetiapine (QUET, 
n=8), olanzapine (OLAN, n=8), risperidone (RISP, n=8), 
aripiprazole (n=8) or haloperidol (n=8) in therapeutic doses 
for an average time period of 39, 40, 45, 38, 30 and 33 days 
respectively showing no significant change in%β as compared 
to antipsychotics-naïve patients (ANOVA followed by 
Bonferroni’s Multiple Comparison Test) (P > 0.05).
FIGURE 6 - Assessment of beta insulin resistance (IR): 
Antipsychotic-naïve patients were treated with olanzapine in 
combination with escitalopram, diazepam (STAT, I.V) and 
haloperidol (STAT, I.M) (OLEDH, n=8), quetiapine (QUET, 
n=8), olanzapine (OLAN, n=8), risperidone (RISP, n=8), 
aripiprazole (n=8) or haloperidol (n=8) in therapeutic doses 
for an average time period of 39, 40, 45, 38, 30 and 33 days 
respectively showing no significant change in IR as compared 
to antipsychotics-naive patients (ANOVA followed by 
Bonferroni’s Multiple Comparison Test) (P > 0.05).
Effect on the level of cholesterol and triglycerides
Significant elevation in the level of cholesterol 
was observed in aripiprazole treated group (ARIP, n=8, 
*P<0.05) when compared to APDs-naive (Figure 7). No 
significance was noticed in the level of triglycerides in any 
of the treated groups (Figure 8) (P>0.05).
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Enzymology
The level of alanine transaminase (Figure 9A) 
was significantly raised in haloperidol treated group 
(HAL, n=8, ***P<0.001) in comparison to APDs-naïve. 
No significance was noticed in the levels of aspartate 
transaminase (Figure 9B) except in that of haloperidol 
treated group (***P<0.001). The level of amylase 
(Figure 9C) was significantly raised in combination 
group (OLEDH, n=8, **P<0.01), olanzapine (OLAN, 
n=8, *P<0.05) and aripiprazole (ARIP, n=8, **P<0.01) 
while that of lipase (Figure 9D) was significantly elevated 
in combination group (OLEDH, n=8, ***P<0.001) and 
risperidone treated group (RISP, n=8, ***P<0.001) 
as compared to APDs-naïve. The level of Creatinine 
Phosphokinase (CPK) (Figure 9E) was noted to be 
unaffected (P>0.05).
Effect on blood urea and creatinine
No significant change was shown in the levels of 
blood urea (P>0.05) (Figure 10A) and serum creatinine 
(Figure 10B) (P>0.05) in any of the treated groups when 
compared to APDs-naïve (P>0.05).
DISCUSSION 
To evaluate changes in glucose homeostasis among 
APDs-naïve patients with first episode psychosis after 
use of olanzapine, quetiapine, risperidone, aripiprazole, 
haloperidol and a combination of olanzapine with 
escitalopram, diazepam and haloperidol, we studied the 
effect of these drugs on pancreatic beta cells thereby 
determining blood glucose, insulin, insulin resistance,% 
β cells function and c-peptide levels in addition to body 
weight. Certain authors have reported insulin resistance 
and impaired beta cells function in patients receiving 
antipsychotic drug (Houseknecht et al., 2006). It has been 
reported in a two weeks study that olanzapine significantly 
decreased insulin level in AAPDs-naïve patients subjected 
to intravenous glucose tolerance test. Beta cells impairment 
has been reported in several animal studies with short term 
use of olanzapine. It has been postulated that these drugs 
might be having acute effects in susceptible individuals 
which may decline over time (Chiu et al., 2010; Chiu et 
al., 2006). Chiu and his colleagues in a study have reported 
hyperinsulinemia, insulin resistance and normal glucose 
level with olanzapine (Chiu et al., 2010). The exact 
mechanism of AAPDs-induced metabolic abnormalities is 
still unknown but additive effects of genetic predisposition 
FIGURE 7 - Effect of selected antipsychotics on cholesterol: 
Antipsychotic-naïve patients were treated with olanzapine 
in combination with escitalopram, diazepam (STAT, I.V) 
and haloperidol (STAT, I.M) (OLEDH, n=8), or quetiapine 
(QUET, n=8), olanzapine (OLAN, n=8), risperidone (RISP, 
n=8), aripiprazole (n=8) or haloperidol (n=8) in therapeutic 
doses for an average time period of 39, 40, 45, 38, 30 and 33 
days respectively showing significant elevation in choleterole 
of aripiprazole treated group as compared to antipsychotics-
naive patients (ANOVA followed by Bonferroni’s Multiple 
Comparison Test) (*P<0.05).
FIGURE 8 - Effect of selected antipsychotics on triglycerides 
(TGs): Antipsychotic-naïve patients were treated with 
olanzapine in combination with escitalopram, diazepam 
(STAT, I.V) and haloperidol (STAT, I.M) (OLEDH, n=8), or 
quetiapine (QUET, n=8), olanzapine (OLAN, n=8), risperidone 
(RISP, n=8), aripiprazole (n=8) or haloperidol (n=8) in 
therapeutic doses for an average time period of 39, 40, 45, 38, 
30 and 33 days respectively showing no significant elevation 
in triglycerides as compared to antipsychotics-naive patients 
(ANOVA followed by Bonferroni’s Multiple Comparison 
Test) (*P<0.05).
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FIGURE 9 - Effect of selected antipsychotics on enzymes: Antipsychotic-naïve patients were treated with olanzapine in combination 
with escitalopram, diazepam (STAT, I.V) and haloperidol (STAT, I.M) (OLEDH, n=8), or quetiapine (QUET, n=8), olanzapine 
(OLAN, n=8), risperidone (RISP, n=8), aripiprazole (n=8) or haloperidol (n=8) in therapeutic doses for an average time period of 
39, 40, 45, 38, 30 and 33 days respectively showing significant elevation in ALT (a) and AST (b) in haloperidol treated groups as 
compared to antipsychotics-naive, significant elevation in amylase (c) of combination group (**P < 0.01), olanzapine (*P < 0.05) 
and aripiprazole treated groups (**P < 0.01) as compared to antipsychotics-naïve patients. Significant elevation was observed in 
lipase (d) of combination group (***P < 0.001) and risperidone treated group (***P < 0.01) as compared to antipsychotics-naïve 
patients. No significant change in CPK (e) as compared to antipsychotics-naïve patients was noticed (P > 0.05) (ANOVA followed 
by Bonferroni’s Multiple Comparison Test).
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to pancreatic dysfunction, primary damage to pancreatic 
beta cells, insulin resistance secondary to weight gain 
and excessive hunger in patients receiving AAPDs have 
been nominated (Ballon et al., 2014; Baptista, Parada, 
Hernandez, 1987; Chiu et al., 2010; Reaven, 2009). In 
contrast to various studies (Arjona et al., 2004; Baptista, 
Parada, Hernadez, 1987; Bergman, Ader, 2005), no 
statistical significance was observed in weight gain with 
any of the selected drugs in our study. The relationship 
between insulin,% beta function, insulin resistance (IR) 
and c-peptide is quite complex; however, the results of 
this study showed no significant change in insulin and 
c-peptide levels which does not support the hypothesis that 
AAPDs cause pancreatic beta cells damage (Kjems et al., 
2000; Sowell et al., 2002). Studies have linked diabetes 
to a direct drug insult to beta cells of the pancreas invoked 
by antipsychotic drugs, although weight gain is not the 
prerequisite of diabetes rather weigh loss could precede 
the diagnosis of diabetes (Sowell et al., 2002). In a short 
study of maximum of 17 days exposure to antipsychotics, 
Sowell and his colleagues are of the opinion that exposure 
to antipsychotics does not increase or decrease the level of 
insulin, which is also supported by our study even in the 
longer drug exposure with a maximum of 45 days (Sowell 
et al., 2002).
These drugs are being reported to be associated 
with metabolic syndrome including dyslipidemias, 
hyperglycemias, obesity, hyperinsulinemia and insulin 
resistance (Chiu et al., 2010). Previous studies have 
shown elevated glucose concentrations together with 
hyperinsulinemia purported to be due to antipsychotic 
drugs (Chiu et al., 2006; Gohlke et al., 2012; Gomez et 
al., 2000). 
Olanzapine-induced pancreatic damage has also 
been reported by our laboratory in a chronic study in rats 
(Shah et al., 2015) and by several other studies (Chiu et 
al., 2010; Doucette, Grenier, Robertson, 2000; Koller et 
al., 2003). In addition to above reports, we showed in our 
study that psychosis by itself, smoking tobacco, charas, 
cannabis and/or use of oral snuff might be other culprits 
that predispose the patients to disturbance in insulin and 
glucose levels. 
Owing to the facts described above, we add the 
following predisposing factors that could disturb glucose 
homeostasis in patients with psychosis; (1): Psychosis by 
itself (2): Antipsychotic drugs (3): Use of narcotics (4): 
Smoking habits (5): Oral snuff (naswar). Dramatically, 
antipsychotic drugs may sometime be correcting insulin 
and blood glucose levels, as observed in our patients 
individually. This dramatic effect of antipsychotics 
may lead to the conclusion that the unkown behavioral 
regulating pathways might be linked somewhere to 
the glucose/lipids regulating/metabolizing pathways. 
Similarly, based on the above results, it could be 
hypothesized that the results of antipsychotics in normal 
individuals with correct behavioral pathways might be 
different in patients with abnormal behavior (Sowell et al., 
2002). The animals used in such studies might be showing 
inconsistent results due to the fact described above. The 
inconsistent results have already been reported by our 
FIGURE 10 - Effect of selected antipsychotics on blood urea (a) and serum creatinine (b): Antipsychotic-naïve patients were treated 
with olanzapine in combination with escitalopram, diazepam (STAT, I.V) and haloperidol (STAT, I.M) (OLEDH, n=8), or quetiapine 
(QUET, n=8), olanzapine (OLAN, n=8), risperidone (RISP, n=8), aripiprazole (n=8) or haloperidol (n=8) in therapeutic doses 
for an average time period of 39, 40, 45, 38, 30 and 33 days respectively showing no significant change in blood urea and serum 
creatinine as compared to antipsychotics-naïve patients (*P < 0.05) (ANOVA followed by Bonferroni’s Multiple Comparison Test).
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laboratory and certain other studies (Baptista, Parada, 
Hernandez, 1987; Shah et al., 2015; Weston-Green, 
Huang, Deng, 2013).
There are reports that APDs cause elevation 
in triglycerides and cholesterol (Lindenmayer et al., 
2003; McIntyre et al., 2001). There are also reports of 
pancreatitis purported to be associated with APDs (Waage, 
Carlsson, Nielsen, 2004). The exact mechanism remains 
unclear, but metabolic dysregulation has been nominated 
especially elevation in triglycrides which in turn causes 
hyperamylasemia and hyperlipasemia (Lattanzi et 
al., 2009). In the current study the effects of different 
antipsychotic drugs on cholesterol and triglycerides were 
studied, and concluded that aripiprazole causes elevation 
in cholesterol, whereas none of the other drugs showed 
any alteration in triglycerides and cholesterol. However, 
hyperamylasemia was noticed in combination group, 
olanzapine and aripiprazole treated groups, that alarm 
disturbance in glucose and insulin in prolonged exposure. 
Similarly, hyperlipasemia was resulted in combination 
and risperidone groups giving possible risk of disturbance 
in lipids if exposed chronically. Studies have reported 
asymptomatic elevation in ALT and AST (Ozcanli et al., 
2006) which is in line with our study showing elevation in 
the level of ALT and AST with haloperidol only. 
Our laboratory and other studies have reported the 
effects of olanzapine and risperidone on the architecture 
of kidneys of rats and it was found that high dose of 
olanzapine (2.5 mg/kg, i.p) and risperidone (1 mg/kg, i.p) 
and low dose of risperidone (0.5 mg/kg, i.p) are associated 
with nephrotoxic effects, including irregularities in tubular 
and glomerular structure, focal necrosis in some areas of 
renal cortex and medulla, cells with pyknotic nuclei and 
eosinophilic cytoplasm etc were noticed, but the studies 
were not supplicated with renal function tests. Our study 
in human, did not show any elevation in serum creatinine 
and blood urea.
Further studies on larger population are required 
with major focus on the biochemistry of drug-naïve 
schizophrenics, and use of narcotics, smoking and oral 
snuff in patients with psychosis. Exposure of diabetic 
subjects to antipsychotics will help in concluding whether 
these drugs correct or worsen the insulin and glucose 
levels.
CONCLUSION 
It is concluded that short term use of APDs is 
not associated with acute alarming events in Pakistani 
population of Pakhtuns territory. It is concluded that 
psychiatric disorders by itself, narcotics, cigarette 
smoking and use of oral snuff may be also be implicated in 
metabolic dysregulations. The effects of APDs on insulin 
and glucose in healthy volunteers might be different than 
in patients with psychiatric disorders.
LIMITATIONS
Antipsychotic drugs are used lifelong; however, 
we followed for a short period of 30 to 45 days. Multiple 
readings of insulin and glucose would better help in 
concluding APDs-induced toxicity. 
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